Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.33 -7.5%	$12.36	$8.04 ▼ $25.88	$361.52M	2.3	424,430 shs	1.20 million shs
ARDX Ardelyx	$3.69 +0.3%	$4.00	$3.21 ▼ $8.06	$882.85M	0.59	4.49 million shs	3.11 million shs
AUPH Aurinia Pharmaceuticals	$8.64 +0.1%	$8.09	$5.20 ▼ $10.67	$1.17B	1.15	1.35 million shs	4.36 million shs
GPCR Structure Therapeutics	$21.08	$23.43	$13.22 ▼ $47.48	$1.21B	-1.87	841,257 shs	382,930 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+8.46%	+4.71%	+15.11%	-45.55%
ARDX Ardelyx	0.00%	+3.65%	-8.44%	-25.15%	-39.61%
AUPH Aurinia Pharmaceuticals	0.00%	+11.20%	+8.14%	+4.22%	+56.81%
GPCR Structure Therapeutics	0.00%	-2.99%	-5.98%	+6.63%	-44.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	3.4802 of 5 stars	4.6	2.0	0.0	2.2	2.5	0.6
ARDX Ardelyx	4.4429 of 5 stars	3.5	3.0	4.4	2.7	2.5	0.6
AUPH Aurinia Pharmaceuticals	2.7534 of 5 stars	3.5	1.0	0.0	2.8	0.8	1.9
GPCR Structure Therapeutics	2.5919 of 5 stars	3.5	3.0	0.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	301.35% Upside
ARDX Ardelyx	3.00	Buy	$10.89	195.09% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.10% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	261.32% Upside

Current Analyst Ratings Breakdown

Latest ARCT, ARDX, GPCR, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.37	N/A	N/A	$8.90 per share	1.50
ARDX Ardelyx	$333.61M	2.65	N/A	N/A	$0.73 per share	5.05
AUPH Aurinia Pharmaceuticals	$235.13M	4.96	$0.31 per share	28.01	$2.68 per share	3.22
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.22	N/A	11.90	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.86	15.43	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)

Latest ARCT, ARDX, GPCR, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
ARDX Ardelyx	1.04	4.12	3.81
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
GPCR Structure Therapeutics	N/A	23.29	23.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
ARDX Ardelyx	58.92%
AUPH Aurinia Pharmaceuticals	36.83%
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
ARDX Ardelyx	4.80%
AUPH Aurinia Pharmaceuticals	12.20%
GPCR Structure Therapeutics	9.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable

ARCT, ARDX, GPCR, and AUPH Headlines

Recent News About These Companies

Structure Therapeutics (NASDAQ:GPCR) Shares Down 4% - Here's Why

June 26 at 4:46 PM | marketbeat.com

Structure Therapeutics' (GPCR) Market Outperform Rating Reaffirmed at JMP Securities

June 25, 2025 | americanbankingnews.com

Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT

June 24, 2025 | msn.com

Structure Therapeutics' (GPCR) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

June 24, 2025 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 4.7% - Time to Buy?

June 23, 2025 | marketbeat.com

Cantor Fitzgerald Reaffirms "Overweight" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

JMP Securities Reiterates "Market Outperform" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 | globenewswire.com

Handelsbanken Fonder AB Buys 215,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

June 13, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.5% - Time to Sell?

June 12, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.4% - Still a Buy?

June 11, 2025 | marketbeat.com

Equities Analysts Set Expectations for GPCR FY2026 Earnings

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Predicts GPCR FY2025 Earnings

June 10, 2025 | marketbeat.com

Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous

June 10, 2025 | seekingalpha.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of "Buy" by Brokerages

June 8, 2025 | marketbeat.com

Bank of America Corp DE Has $1.47 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Makes New $3.09 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 3, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $304,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

May 29, 2025 | marketbeat.com

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 9, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy Recommendation

May 3, 2025 | msn.com

Structure draws new Buy at Citi on oral obesity drug pipeline

May 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, ARDX, GPCR, and AUPH Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.33 -1.08 (-7.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.98 +0.65 (+4.84%)

As of 06/27/2025 05:05 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Ardelyx NASDAQ:ARDX

$3.69 +0.01 (+0.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.02 (+0.41%)

As of 06/27/2025 07:23 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.64 +0.01 (+0.12%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.62 -0.02 (-0.23%)

As of 06/27/2025 07:57 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Structure Therapeutics NASDAQ:GPCR

$21.08 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$21.28 +0.21 (+0.97%)

As of 06/27/2025 07:07 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time